Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy.

Eng H, Scialis RJ, Rotter CJ, Lin J, Lazzaro S, Varma MV, Di L, Feng B, West M, Kalgutkar AS.

Drug Metab Dispos. 2016 May;44(5):692-9. doi: 10.1124/dmd.115.067447. Epub 2016 Feb 17.

PMID:
26888941
2.

Cyclic Penta- and Hexaleucine Peptides without N-Methylation Are Orally Absorbed.

Hill TA, Lohman RJ, Hoang HN, Nielsen DS, Scully CC, Kok WM, Liu L, Lucke AJ, Stoermer MJ, Schroeder CI, Chaousis S, Colless B, Bernhardt PV, Edmonds DJ, Griffith DA, Rotter CJ, Ruggeri RB, Price DA, Liras S, Craik DJ, Fairlie DP.

ACS Med Chem Lett. 2014 Aug 4;5(10):1148-51. doi: 10.1021/ml5002823. eCollection 2014 Oct 9.

3.

Improving on nature: making a cyclic heptapeptide orally bioavailable.

Nielsen DS, Hoang HN, Lohman RJ, Hill TA, Lucke AJ, Craik DJ, Edmonds DJ, Griffith DA, Rotter CJ, Ruggeri RB, Price DA, Liras S, Fairlie DP.

Angew Chem Int Ed Engl. 2014 Nov 3;53(45):12059-63. doi: 10.1002/anie.201405364. Epub 2014 Sep 12.

PMID:
25219505
4.

Mechanism-based pharmacokinetic modeling to evaluate transporter-enzyme interplay in drug interactions and pharmacogenetics of glyburide.

Varma MV, Scialis RJ, Lin J, Bi YA, Rotter CJ, Goosen TC, Yang X.

AAPS J. 2014 Jul;16(4):736-48. doi: 10.1208/s12248-014-9614-7. Epub 2014 May 17.

5.

Quantitative prediction of renal transporter-mediated clinical drug-drug interactions.

Feng B, Hurst S, Lu Y, Varma MV, Rotter CJ, El-Kattan A, Lockwood P, Corrigan B.

Mol Pharm. 2013 Nov 4;10(11):4207-15. doi: 10.1021/mp400295c. Epub 2013 Oct 10.

PMID:
24066726
6.

Quantitative assessment of the contribution of sodium-dependent taurocholate co-transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin.

Bi YA, Qiu X, Rotter CJ, Kimoto E, Piotrowski M, Varma MV, Ei-Kattan AF, Lai Y.

Biopharm Drug Dispos. 2013 Nov;34(8):452-61. doi: 10.1002/bdd.1861. Epub 2013 Oct 3.

PMID:
23996477
7.

Elucidation of the biochemical basis for a clinical drug-drug interaction between atorvastatin and 5-(N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methyl benzoic acid (CP-778875), a subtype selective agonist of the peroxisome proliferator-activated receptor alpha.

Kalgutkar AS, Chen D, Varma MV, Feng B, Terra SG, Scialis RJ, Rotter CJ, Frederick KS, West MA, Goosen TC, Gosset JR, Walsky RL, Francone OL.

Xenobiotica. 2013 Nov;43(11):963-72. doi: 10.3109/00498254.2013.791004. Epub 2013 Apr 30.

PMID:
23631744
8.

High specificity in response of the sodium-dependent multivitamin transporter to derivatives of pantothenic acid.

Chirapu SR, Rotter CJ, Miller EL, Varma MV, Dow RL, Finn MG.

Curr Top Med Chem. 2013;13(7):837-42. Review.

PMID:
23578027
9.

Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin.

Varma MV, Lin J, Bi YA, Rotter CJ, Fahmi OA, Lam JL, El-Kattan AF, Goosen TC, Lai Y.

Drug Metab Dispos. 2013 May;41(5):966-74. doi: 10.1124/dmd.112.050583. Epub 2013 Feb 7.

PMID:
23393219
10.

Optimizing PK properties of cyclic peptides: the effect of side chain substitutions on permeability and clearance().

Rand AC, Leung SS, Eng H, Rotter CJ, Sharma R, Kalgutkar AS, Zhang Y, Varma MV, Farley KA, Khunte B, Limberakis C, Price DA, Liras S, Mathiowetz AM, Jacobson MP, Lokey RS.

Medchemcomm. 2012 Oct;3(10):1282-1289.

11.

pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery.

Varma MV, Gardner I, Steyn SJ, Nkansah P, Rotter CJ, Whitney-Pickett C, Zhang H, Di L, Cram M, Fenner KS, El-Kattan AF.

Mol Pharm. 2012 May 7;9(5):1199-212. doi: 10.1021/mp2004912. Epub 2012 Apr 26.

PMID:
22489626
12.

pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1.

Varma MV, Rotter CJ, Chupka J, Whalen KM, Duignan DB, Feng B, Litchfield J, Goosen TC, El-Kattan AF.

Mol Pharm. 2011 Aug 1;8(4):1303-13. doi: 10.1021/mp200103h. Epub 2011 Jul 11.

PMID:
21710988
13.

Targeting intestinal transporters for optimizing oral drug absorption.

Varma MV, Ambler CM, Ullah M, Rotter CJ, Sun H, Litchfield J, Fenner KS, El-Kattan AF.

Curr Drug Metab. 2010 Nov;11(9):730-42. Review.

PMID:
21189135

Supplemental Content

Loading ...
Support Center